Trials / Recruiting
RecruitingNCT07279636
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation, Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Administration of Alpha-0261 Tablets in Adult Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AlphaMol Science Ltd. (Shanghai) · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alpha-0261 | Oral, tablet |
| OTHER | Placebo | Oral, tablet |
Timeline
- Start date
- 2025-07-21
- Primary completion
- 2026-03-20
- Completion
- 2026-05-30
- First posted
- 2025-12-12
- Last updated
- 2025-12-12
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07279636. Inclusion in this directory is not an endorsement.